Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Amortizatization of Intangibles (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Amortizatization of Intangibles for 10 consecutive years, with $516000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 83.78% to $516000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 69.23% decrease, with the full-year FY2025 number at $4.0 million, down 69.23% from a year prior.
  • Amortizatization of Intangibles was $516000.0 for Q4 2025 at Ultragenyx Pharmaceutical, down from $704000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $4.1 million in Q4 2023 to a low of -$2.1 million in Q4 2021.
  • A 5-year average of $1.0 million and a median of $1.3 million in 2022 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: tumbled 947.33% in 2021, then soared 376.68% in 2023.
  • Ultragenyx Pharmaceutical's Amortizatization of Intangibles stood at -$2.1 million in 2021, then skyrocketed by 178.31% to $1.6 million in 2022, then surged by 148.85% to $4.1 million in 2023, then dropped by 22.5% to $3.2 million in 2024, then crashed by 83.78% to $516000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Amortizatization of Intangibles are $516000.0 (Q4 2025), $704000.0 (Q3 2025), and $1.0 million (Q2 2025).